European Union: Life Sciences, Biotechnology & Nanotechnology

This report examines how deal activity in the life sciences and healthcare sector performed during 2025, highlighting key trends, significant transactions and emerging themes shaping the market. The report also looks ahead to 2026, considering the factors likely to influence M&A activity in Ireland in the year ahead.

On 7 April 2026, the Malta Tax & Customs Administration (MTCA) published official guidelines on the Tax Treatment of Highly Skilled Individuals Rules (these guidelines are issued in terms of Article 96(2)...

In our fifth alert in this EU Pharma Package Series, we provided an analysis of the background and ongoing legal debates regarding the concept of the global marketing authorization (GMA).

(« Décret ») définissant les modalités selon lesquelles le ministre chargé de la santé peut prononcer des pénalités financières...

With formal adoption by both the Council of the EU and the EU Parliament expected by summer 2026, stakeholders should start looking into implementation preparations...

The CNIL and the French National Authority for Health ("HAS") signed a partnership agreement on 10 March 2026 aimed at strengthening best practices...

This week's package of health sector-focused measures from the European Commission contains a number of flagship deliverables under the July 2025 EU Life Sciences Strategy...

In a pivotal moment for a sector that employs around 100,000 people in Ireland and delivers close to €100 billion in exports annually, the Department of Enterprise...

A blueprint for transforming Ireland's clinical trials landscape is set out in the Final Report and Recommendations of the National Clinical Trials Oversight Group (NCTOG), published on 21 November 2025.